LymphoTITAN

Deciphering the Tumor Microenvironment in Relapsed/Refractory Aggressive Lymphomas

Lymphoma Research Group

IIS PUERTA DE HIERRO - SEGOVIA DE ARANA (IDIPHISA)

Project

co-leader

IP: Juan F. Garcia

Project leader

Our main line of work focuses on the identification of mechanisms of lymphomagenesis, especially in Hodgkin lymphoma and aggressive non-Hodgkin lymphomas, as well as molecul ar alterations of prognostic and predictive value. The study of the interactions between the neoplastic cell and the non-neoplastic microenvironment of lymphoma is proposed as a fundamental model. Previous studies have allowed us to identify gene expression profiles associated with therapeutic failure in Hodgkin lymphoma, which include genes, RNA expression and microRNAs relevant to the disease, representing molecular signatures from tumor cells and the non-neoplastic microenvironment. The results will improve the identification of patients resistant to conventional therapies or refractory to immunotherapy, as well as develop new individualized treatment strategies that improve survival.

IP: margarita sánchez-beato

Co-Project leader

The Lymphoma Research Group focus on the analysis of molecular alterations in lymphomas using high-throughput techniques such as ultra-sequencing, expression arrays, SNP arrays, combined with functional assays. Our goal is to identify essential genes/pathways in the survival of lymphomas to improve their diagnosis, prognosis, and treatment. We believe that understanding the molecular alterations present in lymphomas iand their effect on tumor biology should lead to the identification of new therapeutic approaches and molecular markers. This, in turn, should lead to the design of new diagnostic tools applicable to clinical practice, facilitating patient stratification and guiding personalized therapy. We have a predominantly translational nature, combining the analysis of tumor samples from lymphoma patients with functional studies in experimental models. The ultimate aim is to translate the generated knowledge into clinical practice. The group comprises basic researchers with diverse backgrounds (chemists, biotechnologists, biologists) and clinicians from the medical oncology service, enabling multidisciplinary interaction.

SM Rodríguez Pinilla trained via MIR in pathology at the Hospital 12 Octubre (Madrid). Broad her knowledge in Molecular Biology and research at the CNIO in areas such as head and neck, breast and lymphoproliferative processes. She has made different stays in national and international centers of recognized prestige to consolidate and expand her knowledge. She currently works as a Pathologist in the Pathology Department of the Jiménez Díaz Foundation, leads a Line of Research in T-cell Lymphomas and gives class as a Teacher Associate in the faculty of medicine of the Autonomous University of Madrid (UAM). The activity of the group is focused in: 1) Development of projects of translational research. 2) Set up and clinical validation of novel technologies for the molecular diagnosis of patients with hematolymphoid neoplasms.

IP: socorro maría rodríguez-pinilla

IP: javier santos

The group integrates genomics, transcriptomics and proteomics approaches to identify new driver-molecular mechanisms in T-cell lymphoblastic leukaemia/lymphoma (T-LBL and T-ALL). Some of our most relevant findings are: Identification of new mutations and changes in gene expression to propose new therapy strategies; efficacy of γ-secretase inhibitors depends on the MYC gene dosage; use of proteomics to reveal new non-apoptotic functions of FADD protein in these neoplasms; advantages of combined radiation regimens in controlling tumorigenesis that allow better control of healthy tissue homeostasis and facilitate tumour cell death. We are currently interested in evaluating the dysregulation of circular RNAs and long and short ncRNAs, to achieve a comprehensive view of the complex regulatory lncRNA/ circRNA-miRNA-mRNA axes dysregulated in T-cell lymphoblastic neoplasms in the context of a personalized precision medicine.

IP: pablo mínguez

We are a Clinical Bioinformatics laboratory settle in the IIS-Fundación Jiménez Díaz (Madrid, Spain). We use mathematical, computational and statistical methods to study gene and protein regulation under disease stages. Our main research interests are: Genomics Medicine, Genetic diseases, Systems and Network Biology approaches and methods development (https://github.com/TBLabFJD). We are part of research networks such as IMPaCT, TransBioNet, or CIBERER, participate in the B1MG project and several own and collaborative projects. We have led studies applying omics integration approaches to study cancer and diabetes association, protein posttranslational modifications (PTMs) and rare diseases, functional predictions of PTM types, implemented new methods to extract hidden gene-disease, and genetic variant-disease associations. We are or have being part of the development teams of PTMcode DB, STRINGdb, Babelomics, among other tools.

Publications

• Paper 1
• Paper 2
• ....
  

Congresses and seminars

• Communication 1
• Communication 2
• ....
  

Sponsor

Patient associations

Collaborators

news and outreach